These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

441 related articles for article (PubMed ID: 38647237)

  • 41. A prognostic signature based on genes associated with m6A/m5C/m1A/m7G modifications and its immunological characteristics in clear cell renal cell carcinoma.
    He W; Cong Z; Niu C; Cheng F; Yi T; Yao Z; Zhang Y; Jiang X; Sun X; Niu Z; Fu Q
    Sci Rep; 2024 Aug; 14(1):18708. PubMed ID: 39134681
    [TBL] [Abstract][Full Text] [Related]  

  • 42. An m6A/m5C/m1A/m7G-Related Long Non-coding RNA Signature to Predict Prognosis and Immune Features of Glioma.
    Shao D; Li Y; Wu J; Zhang B; Xie S; Zheng X; Jiang Z
    Front Genet; 2022; 13():903117. PubMed ID: 35692827
    [No Abstract]   [Full Text] [Related]  

  • 43. Identification of 4 immune cells and a 5-lncRNA risk signature with prognosis for early-stage lung adenocarcinoma.
    Mu L; Ding K; Tu R; Yang W
    J Transl Med; 2021 Mar; 19(1):127. PubMed ID: 33771173
    [TBL] [Abstract][Full Text] [Related]  

  • 44. An exosomes-related lncRNA prognostic model correlates with the immune microenvironment and therapy response in lung adenocarcinoma.
    Chu D; Chen L; Li W; Zhang H
    Clin Exp Med; 2024 May; 24(1):104. PubMed ID: 38761234
    [TBL] [Abstract][Full Text] [Related]  

  • 45. RNA methylation-related genes of m6A, m5C, and m1A predict prognosis and immunotherapy response in cervical cancer.
    Wang Y; Mao Y; Wang C; Jiang X; Tang Q; Wang L; Zhu J; Zhao M
    Ann Med; 2023 Dec; 55(1):2190618. PubMed ID: 37042849
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Identification of a Seven-lncRNA Immune Risk Signature and Construction of a Predictive Nomogram for Lung Adenocarcinoma.
    Jin D; Song Y; Chen Y; Zhang P
    Biomed Res Int; 2020; 2020():7929132. PubMed ID: 32596372
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Developing a prognostic model using machine learning for disulfidptosis related lncRNA in lung adenocarcinoma.
    Pan Y; Jin X; Xu H; Hong J; Li F; Luo T; Zeng J
    Sci Rep; 2024 Jun; 14(1):13113. PubMed ID: 38849442
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Identification of m6A methyltransferase-related lncRNA signature for predicting immunotherapy and prognosis in patients with hepatocellular carcinoma.
    Li L; Xie R; Lu G
    Biosci Rep; 2021 Jun; 41(6):. PubMed ID: 34027555
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Relapse-related long non-coding RNA signature to improve prognosis prediction of lung adenocarcinoma.
    Zhou M; Xu W; Yue X; Zhao H; Wang Z; Shi H; Cheng L; Sun J
    Oncotarget; 2016 May; 7(20):29720-38. PubMed ID: 27105492
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Immune landscape and a promising immune prognostic model associated with TP53 in early-stage lung adenocarcinoma.
    Wu C; Rao X; Lin W
    Cancer Med; 2021 Feb; 10(3):806-823. PubMed ID: 33314730
    [TBL] [Abstract][Full Text] [Related]  

  • 51. A novel m6A/m5C/m1A score signature to evaluate prognosis and its immunotherapy value in colon cancer patients.
    Liu J; Dou M; Liu X; Lu Y; Lu W
    J Cancer Res Clin Oncol; 2023 Oct; 149(13):11995-12012. PubMed ID: 37421455
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Comprehensive analysis of a chemokine- and chemokine receptor family-based signature for patients with lung adenocarcinoma.
    Fan T; Liu Y; Liu H; Wang L; Tian H; Zheng Y; Zheng B; Xue L; Tan F; Xue Q; Gao S; Li C; He J
    Cancer Immunol Immunother; 2021 Dec; 70(12):3651-3667. PubMed ID: 33977344
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Immune landscape and a novel immunotherapy-related gene signature associated with clinical outcome in early-stage lung adenocarcinoma.
    Bao X; Shi R; Zhao T; Wang Y
    J Mol Med (Berl); 2020 Jun; 98(6):805-818. PubMed ID: 32333046
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Predictions of the dysregulated competing endogenous RNA signature involved in the progression of human lung adenocarcinoma.
    Yang D; He Y; Wu B; Liu R; Wang N; Wang T; Luo Y; Li Y; Liu Y
    Cancer Biomark; 2020; 29(3):399-416. PubMed ID: 32741804
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Comprehensive analysis of a novel signature incorporating lipid metabolism and immune-related genes for assessing prognosis and immune landscape in lung adenocarcinoma.
    Wang Y; Xu J; Fang Y; Gu J; Zhao F; Tang Y; Xu R; Zhang B; Wu J; Fang Z; Li Y
    Front Immunol; 2022; 13():950001. PubMed ID: 36091041
    [TBL] [Abstract][Full Text] [Related]  

  • 56. A gene expression-based immune signature for lung adenocarcinoma prognosis.
    Wang L; Luo X; Cheng C; Amos CI; Cai G; Xiao F
    Cancer Immunol Immunother; 2020 Sep; 69(9):1881-1890. PubMed ID: 32372138
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Seven interferon gamma response genes serve as a prognostic risk signature that correlates with immune infiltration in lung adenocarcinoma.
    Yao B; Wang L; Wang H; Bao J; Li Q; Yu F; Zhu W; Zhang L; Li W; Gu Z; Fei K; Zhang P; Zhang F; Huang X
    Aging (Albany NY); 2021 Apr; 13(8):11381-11410. PubMed ID: 33839701
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Comprehensive Analysis for Predicting Prognoses and Immune Responses of m6A-Related lncRNAs in Women with Lung Adenocarcinoma.
    Wu S; Tu Q; Yuan H; Wu Z; Yang Y; Chen C; Huang C
    Biochem Genet; 2024 Aug; 62(4):2702-2720. PubMed ID: 37999876
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Prognostic model incorporating immune checkpoint genes to predict the immunotherapy efficacy for lung adenocarcinoma: a cohort study integrating machine learning algorithms.
    Yang XL; Zeng Z; Wang C; Wang GY; Zhang FQ
    Immunol Res; 2024 Aug; 72(4):851-863. PubMed ID: 38755433
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Development of the expression and prognostic significance of m
    Xu G; Li C; Di Z; Yang Y; Liang L; Yuan Q; Yang Q; Dong X; Xu S; Wu G
    Cancer Med; 2023 Mar; 12(6):7667-7681. PubMed ID: 36464884
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 23.